Navigation Links
Myriad publishes clinical utility study for Prolaris

SALT LAKE CITY, Utah, March 3, 2014 Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, demonstrating that 65 percent of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test. Prolaris is a 46-gene molecular diagnostic test that has been evaluated in 11 clinical studies with more than 5,000 patients.

"Prolaris is an absolute game changer for urologists because it adds meaningful new prognostic information in terms of risk assessment for prostate cancer patients that will improve their care," said E. David Crawford, M.D., head of the Section of Urologic Oncology at the University of Colorado. "In this study, Prolaris led to major changes in therapies with significant reductions or increases in interventional treatments that were based on patients' unique risk profiles."

PROCEDE 500 is a prospective registry study that was designed to evaluate the impact of the Prolaris test on physician treatment recommendations for patients with prostate cancer. In this study of 305 patients, physicians said they would change their treatment plans in 65 percent of cases after receiving the Prolaris report 40 percent of patients had a reduction in therapeutic burden, while 25 percent had an increase in therapeutic burden independent of treatment strategy (i.e., surgery and/or radiation vs. active surveillance and/or watchful waiting). These results are summarized in Table-1 and Table-2 below:

Table 1: Reduction in Therapeutic Burden Among Trial Participants

Number of Patients in the Study Number of Patients Who Saw a Reduction in Therapeutic Burden Percentage Decrease in Therapeutic Burden
305 122 -40%

Table 2: Increase in Therapeutic Burden Among Trial Participants

Number of Patients in the Study Number of Patients Who Saw an Increase in Therapeutic Burden Percentage Increase in Therapeutic Burden
305 76 +25%

The study also evaluated the shift in treatment paradigms from interventional to non-interventional and non-interventional to interventional. Those data appear in the Table-3 and Table-4 below:

Table 3: Planned Interventional Therapy (e.g., Surgery and/or Radiation)

Number of Patients Planned for Interventional Treatment Before Prolaris Test Score Number of Patients Planned for Interventional Treatment After Prolaris Test Score Percentage Decrease in Interventional Therapy
164 103 -37%

Table 4: Planned Non-Interventional Therapy (e.g., Active Surveillance and/or Watchful Waiting)

Number of Patients Planned for Non-Interventional Treatment Before Prolaris Test Score Number of Patients Planned for Non-Interventional Treatment After Prolaris Test Score1 Percentage Increase in Interventional Therapy
141 108 +23%

Importantly, in this study there was an overall 50 percent reduction in surgical interventions and a 30 percent reduction in radiation treatment. Additionally, 96 percent of the 24 patients with initial "undecided" treatment regimens selected non-interventional options after receiving the Prolaris score. These results demonstrate that the Prolaris test is associated with high clinical utility among urologists.

"In multiple clinical studies, Prolaris was shown to provide personalized risk of cancer-specific death, metastases or biochemical failure beyond what is achievable with the Gleason score, clinical stage and PSA data," said Michael Brawer, M.D. vice president of Medical Affairs at Myriad Genetic Laboratories. "PROCEDE 500 demonstrates that the Prolaris score significantly enhances treatment plans for men with localized prostate cancer."

Myriad Submits Updated Clinical Dossier for Medicare Reimbursement Myriad also announced that it has submitted the PROCEDE 500 data as part of the Prolaris clinical dossier to the Centers for Medicare & Medicaid Services (CMS) for Medicare reimbursement. As previously disclosed based on the robust data set from 11 studies with more than 5,000 patients and six publications in peer-reviewed medical journals the company expects a CMS coverage determination on Prolaris by the end of June 2014.

"More than 30,000 men will die from prostate cancer this year, so there is an urgent need to improve clinical care for patients," said Brawer. "Prolaris adds real value to the healthcare system by reducing unnecessary surgeries or exposure to radiation for men at low risk, while increasing medical interventions for men with aggressive prostate cancer, which we believe will save and improve more lives and potentially save the healthcare system more money."


Contact: Ronald Rogers
Myriad Genetics, Inc.

Related medicine news :

1. AMP celebrates SCOTUS decision on AMP v. Myriad Case
2. The Laser Outlet Highlights Encouraging Study, Showing Myriad Uses of Medical Lasers
3. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
4. Moffitt researcher publishes book on nutritional management of cancer treatment effects
5. Ear, Nose & Throat Journal publishes research on breakthrough treatment for tonsil stones
6. Natural Sciences Repository Publishes Chromatography and Acidic Compounds Resources
7. ASTRO publishes Safety is No Accident: A Framework for Quality Radiation Oncology and Care
8. Annals of Internal Medicine publishes new CDC recommendations on hepatitis C screening
9. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
10. Using an HRA to Comply with San Francisco's HCSO Requirements - Zane Benefits Publishes Information
11. Zane Benefits Publishes Information About Over-the-Counter (OTC) Medicines, Drugs and HRAs
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... ChiliPad , Chili Technology’s temperature-controlled ... through quality sleep. Tim DiFrancesco, training coach for the LA Lakers, recommends ChiliPad ... precisely regulates the surface temperature of each side of the bed so that ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... patient centered orthopedic care. Led by John Vitolo, M.D., the center offers ... condition, the team at Advocare Orthopedic & Sports Medicine is ready to help ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies ... locations, patients can visit Dr. Margulies to experience the best available orthodontic experience in ... title of "NJ Top Dentist"! , Orthodontics is the branch of dentistry that specializes ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ Top Dentist”, ... Tufts School of Dental Medicine in 1935. His father graduated from NYU School ... in dentistry as well as their commitment and passion to the Practice of Dentistry. ...
(Date:11/30/2015)... ... November 30, 2015 , ... The recently ... Poison Data System (NPDS) reveals that in 2014, someone called a poison center ... two million of which were human exposure cases. , The American Association of ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... India , November 30, 2015 ... 2014, and is expected to grow at a CAGR of 7.6% ... was valued at USD 135.6 million in 2014, and is ... 2020. --> According to the new Market Research Report ... invasive, non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
Breaking Medicine Technology: